J Rheumatol
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study.
To assess the efficacy and safety of chondroitin sulfate (CS) 1 g/day per os compared to placebo, in a double blind, randomized, parallel group study, with 3 months treatment followed by a 3 month posttreatment period, in patients with femorotibial osteoarthritis (OA). ⋯ We observed a trend towards efficacy of CS 1 g/day compared to placebo with good tolerability after 3 month treatment, and persistent efficacy one month posttreatment. Further investigations are required to confirm this trend.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
To determine the upper gastrointestinal (GI) tolerability of celecoxib, naproxen, and placebo in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). ⋯ The upper GI tolerability of celecoxib is superior to naproxen. A dose-response relationship between celecoxib and upper GI symptoms was not apparent.
-
Multicenter Study Comparative Study
Development and testing of a systemic lupus-specific risk adjustment index for in-hospital mortality.
Valid comparison of patient outcomes among hospitals requires adjustment for differences in the severity of patients' illness. Disease-specific indexes of severity of illness may permit more accurate risk adjustment than generic indexes. The objective of this study was to develop a systemic lupus-specific risk adjustment index for in-hospital mortality, and to compare its performance to that of the generic Charlson index. ⋯ The SLE-specific risk adjustment index developed from diagnoses recorded in administrative discharge abstracts performed similarly to the generic Charlson index in correctly classifying mortality outcomes, but the SLE-specific index stratified patients by their level of risk of mortality better than the Charlson index. Adjustment for SLE-specific risks of mortality did not alter the association between hospital experience and the risk of in-hospital mortality.
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
To determine the efficacy and safety of the cyclooxygenase 2 (COX-2) specific inhibitor, rofecoxib in patients with osteoarthritis (OA) of the knee. ⋯ Specific inhibition of COX-2 by 25 and 125 mg rofecoxib, administered once daily, resulted in clinically meaningful improvements in patients with OA. This study confirms that COX-2 derived prostanoids are important clinical mediators of pain and other symptoms of knee OA and that inhibition of COX-1 is not required to provide clinical benefit.
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial.
To compare the efficacy and safety of controlled release oxycodone given every 12 h around the clock with immediate release oxycodone-acetaminophen (APAP) given 4 times daily for osteoarthritis (OA) pain. ⋯ Controlled release oxycodone q12h and immediate release oxycodone-APAP qid, added to NSAID, were superior to placebo for reducing OA pain and improving quality of sleep. The active treatments provided comparable pain control and sleep quality. Controlled release oxycodone was associated with a lower incidence of some side effects.